The U.S. vaccines industry keeps developing owing to public health campaigns, biotechnology innovations, preventive health care measures, and modern vaccine platforms that enable immunization for various age segments. Demand is still high for influenza, hepatitis, HPV, pneumococcal disease, meningococcal disease, and emerging infectious diseases. The increasing focus on mRNA vaccines, viral vectors, cold chain developments, and digital health technologies is influencing the development and distribution of vaccines.
According to SNS Insider, the U.S. Human Vaccines Market had been valued at USD 11.72 billion in 2025 and is projected to touch USD 16.22 billion in 2035, recording a CAGR of 3.30%. Globally, the market was valued at USD 44.26 billion in 2025 and is expected to touch USD 68.28 billion in 2035, at a CAGR of 4.43%. The increasing number of immunization programs, increasing incidence of infectious diseases, government policies, and vaccine innovations are contributing to the growth of the market.
Gain Actionable Intelligence on the Human Vaccines Market – Request a Free Sample Report
Why the U.S. Remains a Major Human Vaccines Market
The United States enjoys a robust presence within the vaccines industry because of existing immunization programs, high levels of vaccine awareness, sophisticated healthcare infrastructure, and the early use of innovative technologies such as mRNA and viral vector technology.
The government's immunization programs and research investments will ensure continued research into vaccines as well as their commercialization. The US has a robust biotech and pharmaceutical environment that allows for vaccine testing, manufacture, regulation, and distribution. North America is responsible for about 34.56% of the Human Vaccines Market globally, and this is due to high vaccination rates, extensive R&D budgets, and widespread vaccine technologies.
Companies Advancing the U.S. Human Vaccines Market
Pfizer Inc.
Pfizer is one of the leading firms in the U.S. human vaccines industry, thanks to its strong background in biopharmaceuticals, mRNA technology, facilities and vaccines. This company engages in pneumococcal, meningococcal and COVID-19 vaccination. In August 2025, Pfizer and BioNTech have been approved by the FDA to use their COMIRNATY LP.8.1 mRNA COVID-19 vaccine for 2025-2026 strain coverage.
GlaxoSmithKline plc
GlaxoSmithKline has been present in the area of vaccines for quite some time because of the knowledge in immunology, adjuvants, and existing products in the categories of influenza, shingles, pediatrics, and bacteria. In February 2025, GSK was granted an FDA approval for the Penmenvy, which is a five-in-one meningococcal vaccine that provides coverage against MenABCWY. This vaccine is intended to make adolescent vaccination schedules easier, as well as to provide wider serogroup coverage.
Merck & Co., Inc.
Merck is a prominent American producer of vaccines covering various diseases such as HPV, measles, mumps, hepatitis, and pneumococcal disease. This is due to its strengths in clinical studies, production abilities, as well as collaboration with public health entities. In March 2025, there was an increase in the provision of HPV vaccines by Merck following the rising need for vaccination programs to prevent cervical cancer. Merck will be in a good position to reap from continuous American demand for vaccines.
Market Challenges and Growth Opportunities
The U.S. market still struggles with costly vaccine research and development, long-term clinical trials, extensive regulations, and complicated cold chain management issues. Temperature-dependent products need an effective storage and distribution network, thus driving up operating costs within the supply chain. On the other hand, mRNA technologies, personalized vaccines, digital health, and cold chain monitoring offer possibilities for new immunization strategies. Increased collaboration between the private and public sectors will possibly speed up vaccine research and implementation.
U.S. Human Vaccines Outlook Through 2035
U.S. human vaccines market is projected to grow steadily over the period until 2035 because of preventive medicine, vaccination programs, aging populations, and advances in vaccine technology. In the framework of the growth of the U.S. Human Vaccines Market to USD 16.22 billion in 2035, innovation in mRNA vaccines, age-based immunizations, digital distribution channels, and advanced vaccine delivery technologies is projected to stay important for the market's future development.
